Using a CTC-chip that measures the level of circulating tumor cells in blood can provide an important insight into the prognosis and potential rates of recurrent disease, according to data from a developing study at Massachusetts General Hospital, which was presented at the American Association for Cancer Research (AACR) 101st Annual Meeting 2010. [...]
I have heard back that a number of people have contacted the call center at Dendreon (877-336-3736) and been told to call back at a later date for specific information about getting treatment. I have spoken with Dendreon and they have explained that they are working with the various infusion centers on mapping out specific [...]
Provenge has finally received the long awaited approval from the FDA!!! We all celebrate and look forward to benefiting from its potential to extend our life. Provenge is the first immunologic therapy ever approved in the United States to treat cancer. (In Russia, Antigenics has received approval for an immunological treatment for kidney cancer). The [...]
Join and participate in my new facebook "wiki" page called ADVANCED PROSTATE CANCER.
Researchers from The Cancer Institute of New Jersey (CINJ) have identified candidate drugs that block a key protein responsible for tumor growth. Their research was presented at the recent Annual Meeting of the American Association for Cancer Research (AACR) which I had the good fortune to attend. As we know the common treatment for localized [...]
More news from the AACR Annual Meeting Cruciferous vegetables, we all know them and some of us love them. What we know is that they need to form a part of the standard prostate cancer diet, but some early research shows that a substance found in the them can make prostate cancer cells even more [...]
ABC News has posted a brief story about Provenge. Most of us hope that sometime this week the FDA will finally approve Provenge. To see the brief video interview about Provenge click here. Joel T Nowak, MA, MSW
More from my explorations at the American Association of Cancer Researchers (AACR) conference in Washington, D.C. Abstract 5386 described a study using a thalidomide analogue called lenalidomide (Revlimid), in combination with Taxotere, which currently is the only approved drug for chemotherapy for advanced, metastatic castrate resistant prostate cancer. […]
There were many themes running through the recent American Association of Cancer Researchers (AACR) conference that I just attended in Washington D.C. One significant theme running through the conference was the need to develop personalized medicine to be able to successfully control cancer. This leads us to the question, What is personalized medicine? [...]
I have not had even two seconds to write about anything I saw at the AACR meeting. It will take me a few days to decompress and process my experience. In the mean time I thought I would share the following with you about inflammation and its role in survival and cancer: Researchers from the [...]
